MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >
2019 ASH Symposium – Presentations Available Below

2019 ASH Symposium - Presentations Available Below

Claim Credits Now


Click the links below to view our presentations:

MDS Under the Age of 50
Jane Churpek, MD

CCUS and Clonal Monocytosis of Clinical Significance
Catherine Cargo, MD

Evolutionary Dynamics and Fitness of Clonal Hematopoiesis in Cancer Patients
Elli Papaemmanuil, PhD
Presentation not available

Ineffective Erythropoiesis in MDS
Eva Hellström Lindberg, MD, PhD

Targeted Treatment in MDS
Luca Malcovati, MD

Activity Overview

This symposium will describe recent advances in our understanding of the genetic basis of myelodysplastic syndromes and related myeloid neoplasms, and how these advances are being translated into precision medicine approaches to diagnosis, prognostication and treatment for patients with these hematologic malignancies.

Target Audience

This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.

Learning Objectives

  • Identify how to use molecular genetics in diagnostic and prognostic evaluation of MDS
  • Discuss the fundamental concepts of inherited predisposition to myeloid neoplasms in general and myelodysplastic syndromes in particular
  • Identify how to diagnose and treat patients with MDS under the age of 60
  • Discuss how to diagnose CCUS
  • Discuss how to diagnose clonal monocytosis of clinical significance
  • Explain the molecular classification of MDS
  • Describe the prognostic significance of germline and somatic mutations in MDS
  • List current approaches to treatment of ineffective erythropoiesis in MDS
  • List current approaches to personalized treatment in MDS.

Featured Faculty

Mario Cazzola, MD – Symposium Co-Chair

Professor of Hematology
Department of Molecular Medicine, University of Pavia
Chief, Division of Hematology
Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo
Pavia, Italy

Stephen Nimer, MD – Symposium Co-Chair & MDSF Chairman

Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida, USA

Catherine Cargo, MD

St. James’s University Hospital
Haematological Malignancy Diagnostic Service
Leeds, United Kingdom

Jane Churpek, MD

Medical Director, Comprehensive Cancer Risk
and Prevention Program
University of Chicago Medicine
Chicago, Illinois, USA

Eva Hellström Lindberg, MD, PhD

Professor of Hematology
Karolinska Institute at Karolinska University Hospital Huddinge
Stockholm, Sweden

Luca Malcovati, MD

Associate Professor of Hematology
Department of Molecular Medicine
University of Pavia
Department of Hematology Oncology
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy

Elli Papaemmanuil, PhD

Assistant Professor Computational Oncology Service at
Memorial Sloan Kettering
New York City, New York, USA

Review answers to commonly asked questions or get answers to your questions from an MDS expert